

## Supplementary material

Pabjan P, Brzdęk M, Chrapek M, et al. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings. *Pol Arch Intern Med.* 2021; 131: 16094. doi:10.20452/pamw.16094

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1** GT1b infected patients with liver cirrhosis depending on the treatment regimens

Parameter	Genotype-specific regimens n=136	Pangenotypic regimens n=32	P value
Gender, females/males, n(%)	65 (47.8%)/71(52.2%)	16 (50%)/16 (50%)	0.82
Age (years), median (Q1, Q3); min.-max.	60.0 (50.8, 69.0); 28-89	61.0 (45.5, 72.0); 30-80	0.94
Females	62.0 (56.0, 69.0); 32-88	70.0 (58.8, 73.8); 30-80	0.19
Males	57.0 (46.0, 66.0); 28-89	53.5 (39.0, 61.2); 35-80	0.26
BMI (kg/m <sup>2</sup> ), median (Q1, Q3); min-max Median (Q1, Q3)	27.0 (24.2, 29.8); 17.5-44.9	25.8 (22.9, 28.8); 19.4-41.2	0.17
Comorbidities, n(%)			
Any comorbidity	132 (97.1%)	29 (90.6%)	0.13
Hypertension	67 (49.3%)	16 (50%)	0.94

Diabetes	31 (22.8%)	9 (28.1%)	0.52
Renal disease	14 (10.3%)	3 (9.4%)	1
Autoimmune diseases	10 (7.4%)	0	0.21
Non-HCC tumors	8 (5.9%)	1 (3.1%)	1
Other	117 (86%)	26 (81.3%)	0.19
Concomitant medications, n(%)	124 (91.2%)	27 (84.4%)	0.32
Use of diuretics, n(%)	58 (42.6%)	14 (43.8%)	0.91
History of previous therapy, n			< 0.0001
Treatment-naïve	75 (55.1%)	32 (100%)	
Nonresponder	33 (24.3%)	0	
Relapser	19 (14%)	0	
Discontinuation due to safety reason	9 (6.6%)	0	
History of hepatic decompensation, n			
Ascites	18 (13.2%)	4 (12.5%)	1
Encephalopathy	10 (7.4%)	0	0.21
Documented esophageal varices, n(%)	58 (42.6%)	10 (31.3%)	0.23
Hepatic decompensation at baseline, n(%)			
Moderate ascites – responded to diuretics	14 (10.3%)	3 (9.4%)	1

Tense ascites – not responded to diuretics	2 (1.5%)	0	1
Encephalopathy	5 (3.7%)	0	0.58
Child-Pugh, n(%)			0.90
A	115 (84.6%)	28 (87.5%)	
B	17 (12.5%)	3 (9.4%)	
C	4 (2.9%)	1 (3.1%)	
MELD, n(%)			0.18
<15	121 (89%)	29 (90.6%)	
15-18	15 (11%)	2 (6.3%)	
19-20	0	0	
>20	0	1 (3.1%)	
HCC history, n(%)	6 (4.4%)	0	0.6
OLTx history, n(%)	0	0	-
HBV coinfection (HBsAg+), n(%)	2 (1.5%)	0	1
HIV coinfection, n(%)	0	0	-
ALT IU/L, median (Q1, Q3); min-max	79.5 (48.0, 124.0); 13.0 - 414.0	66.0 (46.2, 115.0); 23.0 - 366.0	0.33
Bilirubin mg/dL, median (Q1, Q3); min-max	1.2 (0.9, 1.7); 0.4 - 14.5	1.1 (0.9, 1.3); 0.5 - 21.3	0.89
Albumin g/dL, median (Q1, Q3); min-max	3.7 (3.3, 4.0); 2.3 - 4.9	3.6 (3.3, 3.9); 2.5 - 4.3	0.88

Creatinine mg/dL, median (Q1, Q3); min-max	0.9 (0.8, 1.0); 0.6 - 2.7	0.9 (0.7, 0.9); 0.6 - 2.4	0.19
Hemoglobin g/dL, median (Q1, Q3); min-max	13.6 (12.3, 14.5); 8.9 - 17.0	13.9 (12.8, 15.1); 10.5 - 17.9	0.23
Platelets, x1000/ $\mu$ L, median (Q1, Q3); min-max	95.5 (70.2, 137.5); 25.0 - 422.0	106.5 (77.8, 152.2); 43.0 - 289.0	0.15
HCV RNA x10 <sup>6</sup> IU/mL, median (Q1, Q3); min-max	0.5 (0.1, 1.5); 0.002-67.0	0.8 (0.3, 1.8); 0.004-19.2	0.1
Abbreviations: BMI, body mass index; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ALT alanine transaminase; HCV RNA, ribonucleic acid of hepatitis C virus; MELD, Model End-Stage Liver Disease; OLTx, orthotopic liver transplantation; Q1, lower quartile; Q3, upper quartile			

**Table S2** Univariable predictors of non-response to antiviral therapy

<b>Parameter</b>	<b>Univariable OR</b>	<b>95% CI</b>	<b>P value</b>
Males	NC	-	-
Age years	1	0.95-1.04	0.91
BMI kg/m <sup>2</sup>	1.09	0.95-1.24	0.21
Genotype-specific regimen	1.31	0.26-6.56	0.74
Any comorbidity	2	0.24-16.37	0.52
Hypertension	0.26	0.03-2.09	0.2
Diabetes	2.55	0.51-12.82	0.26
Renal disease	1.74	0.21-14.39	0.61
Autoimmune diseases	NC	-	-

Non-HCC tumors	NC	-	-
Concomitant medications	3.94	0.48-32.15	0.2
Liver fibrosis F4 (vs. F0-F3)	3.89	0.96-15.73	0.06
DAA-experienced	27.64	2.73-279.66	0.0049
HCC history	NC	-	-
OLTx history	NC	-	-
HBV coinfection (HBsAg+)	NC	-	-
HIV coinfection	NC	-	-
ALT IU/L	1	0.99-1.01	0.78
Bilirubin mg/dL	1.11	0.81-1.52	0.52
Albumin g/dL	0.25	0.06-0.93	0.0392
Creatinine mg/dL	1.17	0.42-3.3	0.76
Hemoglobin g/dL	1.09	0.69-1.71	0.71
Platelets, x1000/ $\mu$ L	0.99	0.98-1	0.06
HCV RNA x10 <sup>6</sup> IU/mL	0.93	0.69-1.26	0.63

Abbreviations: ALT, alanine transaminase; BMI, body mass index; DAA, direct-acting antiviral; F, fibrosis; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma, hepatitis C virus; HCV RNA, ribonucleic acid of hepatitis C virus; HIV, human immunodeficiency virus; HCV; NC, not calculable (0 in nonresponders); OLTx, orthotopic liver transplantation; OR; odds ratio